Crack Open the Champagne, AiCuris’ Antiviral Launched in Germany
Update (23/02/2018): Merck Sharp & Dohme (MSD), licensee of AiCuris, has launched letermovir in Germany under…
Update (23/02/2018): Merck Sharp & Dohme (MSD), licensee of AiCuris, has launched letermovir in Germany under…
Now that we've got the bad news out of the way, we're here to spread…
This week marks the WHO's World Antibiotic Awareness Week. We had a look at some of…
AiCuris' Pritelivir has now secured FDA endorsement in the form of a Fast Track Designation…
Fewer antibiotics are produced as development costs rise. We reached out to a few companies…
AiCuris' candidate pritelivir has shown to perform better than current standard antiviral treatments against genital…
AiCuris is developing a new antibiotic that might bring hope for patients in which all…
AiCuris' Letermovir succeeds in Phase III after being licensed to MSD in a record €442.5M deal. It acts on a…
Update (09/05/2017): AiCuris has started a Phase II trial, PRIOH-1, with the oral version of…
AiCuris is a Biotech company based on the Bayer Life Sciences park in Wuppertal (Germany).…